These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33502260)

  • 1. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
    Louis C; Edeline J; Coulouarn C
    Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
    Wang J; Ilyas S
    Expert Opin Investig Drugs; 2021 Apr; 30(4):429-438. PubMed ID: 33322977
    [No Abstract]   [Full Text] [Related]  

  • 3. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?
    Wang J; Loeuillard E; Gores GJ; Ilyas SI
    Expert Opin Ther Targets; 2021 Oct; 25(10):835-845. PubMed ID: 34806500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
    Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
    Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma: novel therapeutic targets.
    Sato K; Glaser S; Alvaro D; Meng F; Francis H; Alpini G
    Expert Opin Ther Targets; 2020 Apr; 24(4):345-357. PubMed ID: 32077341
    [No Abstract]   [Full Text] [Related]  

  • 8. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
    Høgdall D; Lewinska M; Andersen JB
    Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cholangiocarcinoma.
    Mertens JC; Ilyas SI; Gores GJ
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine.
    Carloni R; Rizzo A; Ricci AD; Federico AD; De Luca R; Guven DC; Yalcin S; Brandi G
    Transl Oncol; 2022 Nov; 25():101514. PubMed ID: 35977458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment.
    Minini M; Fouassier L
    Curr Oncol; 2023 Apr; 30(4):4185-4196. PubMed ID: 37185432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma.
    Hua S; Gu X; Jin H; Zhang X; Liu Q; Yang J
    Biomed Pharmacother; 2024 Aug; 177():117080. PubMed ID: 38972151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
    Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
    Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.
    Cadamuro M; Lasagni A; Lamarca A; Fouassier L; Guido M; Sarcognato S; Gringeri E; Cillo U; Strazzabosco M; Marin JJ; Banales JM; Fabris L
    Expert Opin Investig Drugs; 2021 Apr; 30(4):377-388. PubMed ID: 33622120
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunology and immunotherapy of cholangiocarcinoma.
    Greten TF; Schwabe R; Bardeesy N; Ma L; Goyal L; Kelley RK; Wang XW
    Nat Rev Gastroenterol Hepatol; 2023 Jun; 20(6):349-365. PubMed ID: 36697706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
    Banales JM; Cardinale V; Carpino G; Marzioni M; Andersen JB; Invernizzi P; Lind GE; Folseraas T; Forbes SJ; Fouassier L; Geier A; Calvisi DF; Mertens JC; Trauner M; Benedetti A; Maroni L; Vaquero J; Macias RI; Raggi C; Perugorria MJ; Gaudio E; Boberg KM; Marin JJ; Alvaro D
    Nat Rev Gastroenterol Hepatol; 2016 May; 13(5):261-80. PubMed ID: 27095655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the Notch signaling in cholangiocarcinoma.
    Cigliano A; Wang J; Chen X; Calvisi DF
    Expert Opin Ther Targets; 2017 May; 21(5):471-483. PubMed ID: 28326864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current challenges to underpinning the genetic basis for cholangiocarcinoma.
    Cigliano A; Chen X; Calvisi DF
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):511-526. PubMed ID: 33888034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.
    Kabbara KW; Cannon T; Winer A; Wadlow RC
    Oncology (Williston Park); 2022 Aug; 36(8):492-498. PubMed ID: 36001788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.